創勝集團-B(06628.HK)擬全球發售4033萬股 引入淡馬錫等多家基石
格隆匯9月14日丨創勝集團-B(06628.HK)發佈公告，公司擬全球發售4033萬股股份，其中香港發售股份403.3萬股，國際發售股份3629.7萬股，另有15%超額配股權；2021年9月14日至9月17日招股，預期定價日爲9月17日；發售價每股發售股份15.80港元-16.00港元，每手買賣單位500股，入場費約8081港元；高盛及中金公司爲聯席保薦人；預期股份將於2021年9月29日於聯交所主板掛牌上市。
集團是一家集發現、研究、開發、製造及業務拓展能力爲一體的臨牀階段生物製藥公司。集團的管理團隊及主要業務(包括臨牀開發、監管準入及業務拓展)位於中國及美國，而集團的發現、研發、工藝開發及生產團隊均位於中國。集團採用全球化策略以最大程度提高運營效率。同時，集團利用高效的監管審批路徑以加快進行在美國的試驗用新藥(IND)申請及前期臨牀試驗以及推進在中國來自龐大患者人羣的巨大醫療需求缺口的適應症的臨牀試驗。集團按可讓各試驗的臨牀數據用於進行彙總分析及支持註冊(包括中國、美國及歐洲國家)的方式設計試驗。此外，多地區臨牀試驗的臨牀數據使所研究的藥物可在集團計劃的國家及地區進行未來適應症擴展。
集團已與基石投資者訂立基石投資協議，據此，基石投資者已同意在滿足若幹條件情況下，認購或促使其指定實體認購以發售價購買的總金額約6800萬美元(約5.28億港元)的相關數目發售股份。基石投資者包括LAV、淡馬錫、QIA、及中國國有企業結構調整基金。
集團估計，假設超額配股權不獲行使，及假設發售價爲每股發售股份15.90港元(即發售價範圍中位數)，集團將收取所得款項淨額約5.706億港元。集團擬將從是次發售所收取所得款項淨額的82%用於集團管線候選產品的研發、爲進行中及計劃中的臨牀及臨牀前試驗、籌備註冊備案以及其他與商業化集團四款主打產品有關的步驟或活動撥資；所得款項淨額的8%用於爲擴充管線及開發技術的業務發展撥資，重點用於能夠與集團的現有管線形成協同效應並有良好前景的臨牀證據的腫瘤資產及╱或能夠補充集團現有發現及開發平臺的技術平臺(如ADC)、小分子靶向療法及其他先進新技術；及所得款項淨額的10%用作一般營運資金及一般營運費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
